Shares of the company, which doesn't have any drug in the market, tripled to $176.94 in extended trading.
Puma said on Tuesday it plans to file for marketing approval of neratinib, code named PB272, in the first half of 2015.
Read more
Puma says cancer drug meets trial goal, shares soar
July 22, 2014 10:06 PM
16 0